Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254)

NCT02163356 is registered in ClinicalTrials.gov with South Plains Oncology Consortium as lead sponsor.

NCT NCT02163356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02163356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254)
Lead sponsor
South Plains Oncology Consortium
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2014
Completion date
May 31, 2018
Enrollment
4 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, recurrent neuroblastoma